BioAge Labs (NASDAQ:BIOA) Trading Up 8.7% – Here’s Why

BioAge Labs, Inc. (NASDAQ:BIOA) shares rose 8.7% during trading on Friday . The company traded as high as $17.76 and last traded at $17.8730. Approximately 82,522 shares traded hands during trading, a decline of 86% from the average daily volume of 586,678 shares. The stock had previously closed at $16.45.

Analyst Upgrades and Downgrades

BIOA has been the topic of a number of recent research reports. Roth Mkm initiated coverage on BioAge Labs in a research note on Wednesday, May 27th. They set a “buy” rating and a $36.00 price objective on the stock. Citigroup boosted their price objective on BioAge Labs from $15.00 to $52.00 and gave the stock a “buy” rating in a research note on Tuesday, March 10th. Weiss Ratings restated a “sell (d-)” rating on shares of BioAge Labs in a research note on Friday, April 24th. Wall Street Zen cut BioAge Labs from a “hold” rating to a “sell” rating in a research note on Sunday, May 17th. Finally, Oppenheimer initiated coverage on BioAge Labs in a research note on Wednesday, February 25th. They set an “outperform” rating and a $60.00 price objective on the stock. Six analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $43.50.

BioAge Labs Stock Up 8.4%

The company has a 50 day moving average of $17.18 and a 200 day moving average of $17.02. The firm has a market cap of $792.99 million, a price-to-earnings ratio of -7.43 and a beta of 0.94.

BioAge Labs (NASDAQ:BIOA) last announced its quarterly earnings data on Friday, May 8th. The company reported ($0.52) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.71) by $0.19. BioAge Labs had a negative return on equity of 29.40% and a negative net margin of 871.75%.The firm had revenue of $2.77 million for the quarter. As a group, equities research analysts expect that BioAge Labs, Inc. will post -2.68 earnings per share for the current fiscal year.

Institutional Trading of BioAge Labs

Institutional investors and hedge funds have recently bought and sold shares of the company. GSA Capital Partners LLP acquired a new stake in BioAge Labs during the third quarter valued at approximately $181,000. R Squared Ltd acquired a new stake in BioAge Labs during the third quarter valued at approximately $154,000. Nano Cap New Millennium Growth Fund L P acquired a new stake in BioAge Labs during the fourth quarter valued at approximately $1,058,000. Octagon Capital Advisors LP raised its stake in BioAge Labs by 9.4% during the first quarter. Octagon Capital Advisors LP now owns 1,748,000 shares of the company’s stock valued at $30,573,000 after buying an additional 150,000 shares in the last quarter. Finally, Bank of Nova Scotia acquired a new stake in BioAge Labs during the first quarter valued at approximately $180,000.

About BioAge Labs

BioAge Labs (NASDAQ: BIOA) is a clinical-stage biotechnology company focused on discovering and developing therapies that address age-associated diseases. The company leverages its proprietary analytics platform to mine large-scale human biological data for insights into the molecular mechanisms of aging. By targeting fundamental aging pathways, BioAge aims to create interventions that extend healthspan and treat conditions that disproportionately affect older populations.

At the core of BioAge’s operations is its integrated drug discovery platform, which combines human omics datasets, machine learning algorithms and experimental validation to identify novel drug targets.